MarketResearchFuture.com adds a new Report named as “Global Pancreatic Cancer Market, 2018 Market Research Report” to its research database. The report spread across 146 pages with table and figures in it. Pancreatic Cancer Market research report includes a brief on these trends that can help the businesses operating in the industry to understand the market and strategize for their business expansion accordingly.

Rising rates in tobacco consumption, increasing cigarette smokers are likely to enhance the growth of Pancreatic Cancer Market. Additionally, rising prevalence of cancer, increase in intake of alcohol, growing obesity rates, and growing awareness pertaining to various treatment options available are propelling the market growth at a Global level. The Global Pancreatic Cancer Market is expected to grow at a CAGR of 8.1% during the forecast period 2018-2023.

Founded in 1980, and headquartered at US, Celgene Corporation is a biopharmaceutical company aimed in the detection and development of treatments for various cancers and inflammatory diseases. Celgene Corporation has its presence all over the world. The firm has focused on various inorganic and organic growth strategies to enhance its services and increase its patient base. For instance in the year 2015, Celgene Corporation received approval from European Commission (EC) for ABRAXANE, a nanotechnology therapy for the treatment of metastatic pancreatic cancer. The firm has been focusing on improving lives of patients with pancreatic cancer. For instance in 2015, Celgene Corporation invested 30% of its revenue on research and development to produce advanced technologies to support patients with pancreatic cancer. By this approval and high research and development expenditure, the firm aims to focus on patient needs and increase its customer base.

Novartis AG

Founded in 1895, and headquartered in Switzerland, Novartis AG is engaged in the manufacture and development of a wide range of healthcare products. In 2016, Novartis and Pfizer collaborated to form a study on tumors driven by mutations in a gene called KRAS that causes cancer. Additionally, in 2017 Novartis and Perthera partnered to support clinical trials for lung cancer patients. This collaboration and partnership enables the firm to widen its foothold in various geographies.

Regional Analysis

The Americas dominate the Global Pancreatic Cancer Market owing to well-developed technology, increasing patient with cancer, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities and the concentration of major companies have fuelled the growth of the market in this region.

Europe holds the second position in the global pancreatic cancer market owing to the government support for research & development and availability of funds for research. This is expected to continue to drive the European market over the forecasted period. For instance, countries like Germany and France are increasing investment in the healthcare domain.

Asia Pacific is the fastest growing pancreatic cancer market owing to the presence of rapidly developing healthcare technology, huge patient population, and high healthcare expenditure. Moreover, increasing demand for new treatment methods in countries like India and South Korea is likely to emerge as the fastest growing market across the globe.

On the other hand, in the Middle East and Africa, pancreatic cancer has become a huge problem due to limited screening, ignorance of diseases, and poor access to treatment.

Segmentations

The global pancreatic cancer market is segmented on the basis of types, treatment, and end user.

On the basis of the type, it is segmented into endocrine pancreas cancer, exocrine pancreas cancer, and others.

On the basis of the treatment, it is segmented into chemotherapy, surgery & radiation therapy, targeted therapy, biologic therapy, hormone therapy, and others. Furthermore, the chemotherapy is segmented into antimetabolites, anthracyclines, taxanes, and alkylating agents. The targeted therapy is sub-segmented into tyrosine kinase inhibitors and monoclonal antibodies. And the hormone therapy is sub-segmented into estrogen-receptor modulators, aromatase inhibitors, and others.

On the basis of the end user, it is segmented into hospitals & clinics, research institute, and others.

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around

more

Event Details

PULSUS group cordially welcomes researchers, academicians, students and business professionals in the field of Cancer Science and Therapy from around the world to participate in the upcoming “2nd World Congress on Advanced Cancer Science & Therapy” to be held at Dubai, UAE during January 28-29, 2019. The meeting for this year will revolve around the theme “An Assembly of Curious Facts and Cure for Cancer” thus relaying the most cutting-edge findings in this field.

The two-day meeting is going to be an event to look forward for its enlightening symposiums & workshops from established experts in cancer therapy, potential keynote talks from eminent speakers, informative oral sessions and innovative poster presentations.

Cancer Therapy 2019 is an extraordinary event that invites participants from different leading universities, clinical research institutions and various diagnostic companies to share their research experiences in all aspects of this rapidly expanding field and provides an opportunity to meet and communicate with leading doctors, surgeons, scientists, academic professionals from around the world and listen to top speakers on new developments that impact and advance future of cancer science. It serves as a global platform to know about the current developments and new approaches in the field of cancer science and therapy. It will also prove to be a brilliant open door for businesses keen on expanding their global market reach. This event is an effort to understand the underlying new techniques which are amended to increase effectiveness, accuracy, sustainability, and quality of life.